terms of facility, personnel and product portfolio. In 2017, company recorded a profitable year with revenues of 6 M EUR (7.2 M USD) with a team of 16 engineers (375kEUR/employee), 12 M EUR in 2018 with 29 employees ( 344 kEUR/employee). Since July 2019, company has been split into two company groups based on the activity. Electro-optical systems for defence is covered by companies Brolis Semiconductors UAB (Lithuania) and Brolis Photonics Solutions Ltd (UK), whereas photonic sensor technology is covered by Brolis Sensor Technology (Lithuania) and Brolis Semiconductors BVBA (Belgium). Currently, the company group has 40+ employees across three European locations. Company is now privately owned by Vizbaras family, Light conversion, Zabolis and ARP Invest.

Brolis develops unique non-invasive medical sensor technology for blood constituent monitoring based on Brolis proprietary light-source technology merged with photonic integrated circuit technology utilizing CMOS manufacturing process. New sensor technology allows access to multiple molecules including such critical target molecules as glucose, lactates, urea, albumin, ammonia and others. Brolis approach offers radical differentiation vs other contenders in the market - company makes its own custom and unique integrated photonic sensors that emit laser radiation for DIRECT interaction with target molecule. This allows real-time signal monitoring and opens completely new opportunities for wearable technology in the digital health and sports markets.

Since 2012, Brolis has created a strong IP portfolio of 14 patents (2 granted and 12 pending).

Company operates across three locations: headquarters and III-V semiconductor technology facility in Vilnius, Lithuania, Integrated photonics R&D office in Ghent, Belgium and defence sales office and system assembly site in Larne, Northern Ireland, UK.